Herpelāns (Aciclovir)

Herpelāns is indicated for the treatment of infections caused by herpes simplex virus and varicella‑zoster virus. It is commonly prescribed to manage acute episodes and to reduce the severity and duration of symptoms associated with these viral conditions.

• Primary genital herpes outbreaks caused by HSV‑1 or HSV‑2.
• Oral herpes (cold sores) due to HSV infection.
• Chickenpox (varicella) in immunocompetent patients.
• Shingles (herpes zoster) affecting dermatomal skin areas.
• Post‑exposure prophylaxis for susceptible individuals after exposure to HSV.

• Aciclovir, the active component of Herpelāns, is a nucleoside analogue that is selectively phosphorylated by viral thymidine kinase. The monophosphate is then converted by cellular kinases to aciclovir triphosphate, which competitively inhibits viral DNA polymerase. This inhibition blocks the elongation of viral DNA chains, preventing viral replication while having minimal effect on host cellular DNA synthesis. The drug accumulates preferentially in infected cells, enhancing its antiviral selectivity.

Adverse reactions to Herpelāns are generally mild, but some patients may experience more serious events. The frequency and severity of side effects vary among individuals.

Common

• Moderate nausea, vomiting, or loss of appetite.
• Persistent headache, dizziness, or light‑headedness.
• Loose stools, abdominal cramps, or mild stomach upset.
• Transient rash, itching, or localized skin redness.
• Noticeable fatigue, general weakness, or malaise.
• Temporary rise in liver enzymes without clinical symptoms.

Serious

• Acute renal impairment or failure, especially in patients with existing kidney disease or dehydration.
• Severe hypersensitivity reactions such as anaphylaxis, Stevens‑Johnson syndrome, or toxic epidermal necrolysis.
• Blood dyscrasias including neutropenia, thrombocytopenia, or anemia.
• Neurological events like seizures or encephalopathy in patients with pre‑existing CNS disorders.

When prescribing Herpelāns, clinicians should consider several precautionary measures to ensure safe use and to minimize the risk of adverse outcomes.

• Assess renal function before initiating therapy, especially in elderly or dehydrated patients.
• Adjust dose in individuals with impaired kidney function or those receiving nephrotoxic drugs.
• Use caution in patients with known hypersensitivity to aciclovir or related compounds.
• Monitor liver enzymes during prolonged treatment courses.
• Avoid use during the first trimester of pregnancy unless benefits outweigh potential risks.
• Evaluate for concurrent immunosuppressive therapy, which may increase infection severity.

Herpelāns may interact with other medicines, affecting its efficacy or increasing toxicity. Awareness of these interactions helps guide appropriate co‑administration.

Avoid

• Co‑administration with probenecid, which can markedly increase aciclovir plasma concentrations.
• Concurrent use of nephrotoxic agents such as aminoglycosides or non‑steroidal anti‑inflammatory drugs (NSAIDs) without dose adjustment.
• Combining with other antiviral nucleoside analogues that share the same metabolic pathways.

Use with caution

• Co‑administration with cimetidine may slightly raise aciclovir levels; monitor renal function.
• Concomitant use of immunosuppressants (e.g., corticosteroids, azathioprine) may require closer clinical observation.
• Use with other drugs cleared renally (e.g., digoxin, metformin) warrants dose evaluation.